TABLE 1.
Antiproliferative effect of BBIT20, cisplatin and olaparib, in a panel of human breast cancer, ovarian cancer and non-malignant cells
| IC50 (μM) | ||||
|---|---|---|---|---|
|
|
||||
| Human cells | BBIT20 | Cisplatin | Olaparib | |
| wtBRCA1-expressing cells | T47D | 11.5 ± 3.0 | 5.9 ± 0.05 | 30.0 ± 2.4 |
| MCF-7 | 11.1 ± 1.6 | 11.9 ± 3.4 | 39.2 ± 2.8 | |
| OVCAR-3 | 13.9 ± 1.7 | 3.2 ± 0.05 | 42.0 ± 4.5 | |
| SKOV-3 | 8.9 ± 2.5 | 12.0 ± 1.1 | 98.0 ± 1.9 | |
| BRCA1 LOH cells | MDA-MB-231 | 5.6 ± 1.4 | 12.1 ± 1.1 | 50.9 ± 1.7 |
| MDA-MB-468 | 4.3 ± 1.2 | 2.3 ± 0.3 | 43.0 ± 5.9 | |
| SK-BR-3 | 5.7 ± 1.4 | 14.5 ± 2.6 | 27.5 ± 3.5 | |
| mutBRCA1-expressing cells | HCC1937 (5382insC) | 5.7 ± 1.3 | 8.6 ± 0.9 | 30.5 ± 1.3 |
| IGROV-1 (280delA) | 4.6 ± 1.5 | 5.8 ± 0.7 | 15.9 ± 2.1 | |
| Non-malignant cells | HFF-1 | 33.6 ± 3.2 | 9.3 ± 0.9 | 36.0 ± 1.1 |
| MCF10a | 29.5 ± 2.7 | 2.3 ± 0.35 | 86.0 ± 3.1 | |
| Patient-derived ovarian cancer (PD-OVCA) cells | ||||
| Pathogenic mutBRCA1 | PD-OVCA #1 | 2.68 ± 0.57 | 15.53 ± 1.41 | 31.92 ± 5.08 |
| PD-OVCA #9 | 5.11 ± 1.03 | 8.40 ± 1.38 | 15.64 ± 3.49 | |
| Benign mutBRCA1 | PD-OVCA #41 | 14.09 ± 0.88 | 4.38 ± 1.05 | 64.58 ± 4.45 |
| wtBRCA1-expressing cells | PD-OVCA #49 | 15.10 ± 1.42 | 8.31 ± 1.76 | 23.56 ± 1.93 |
| PD-OVCA #62 | 14.24 ± 2.85 | 6.52 ± 1.51 | 56.17 ± 5.22 | |
Note: IC50 values were determined by Sulforhodamine B (in immortalized cells) or CellTiter96®Aqueous one solution cell proliferation assay (MTS; in PD-OVCA cells) assay, after 48 h of treatment. Data are mean ± SD (n = 5, with two replicates each).
Abbreviations: LOH, loss of heterozygosity; mut, mutant; patient-derived ovarian cancer, PD-OVCA; wt, wild-type.